Lesen Sie hier weiter... |  Drucken |  PDF

Ähnliche Artikel

• FDA Approves Abbott's XIENCE(TM) V Drug Eluting Stent
• Resverlogix's Lead Drug Featured in Key Scientific Publication
• XIENCE(TM) V Drug Eluting Stent from Abbott Reduces Major Adverse Cardiac Events in Small Vessel Patients Out to One Year
• Biosensors DES Demonstrates Equivalent Safety and Efficacy to Industry Leading DES in First'Real World, All Comers' Clinical Study
• XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
• FDA erteilt Zulassung für Taclonex Scalp(R), eine einmal tägliche Behandlung mittelschwerer bis schwerer Psoriasis der Kopfhaut
• Industry Leaders Select Resverlogix's RVX-208 Among Top 10 Most Promising Drugs
• EMEA erteilt Kiadis Pharmas Hauptprodukt ATIR(TM) den Orphan-Drug-Status
• First Pivotal Trials Begin for Boehringer Ingelheim's Novel Triple Angiokinase Inhibitor Vargatef(TM) (BIBF 1120)
• PRA International spricht während des europäischen Kongresses"Partnerships in Clinical Trials"über Sponsor-CRO-Partnerschaftsstrategien

isotechnika inc. Pressemitteilungen News | PresseEcho.de

Drug-Eluting Coronary Stents Utilizing Isotechnika's Lead Drug Receive Approval to Enter Clinical Trials to enter a Phase 1 clinical trial as the drug

MedCrawler.de - Die Suchmaschine für Medizin und Gesundheit

MedCrawler.de - Die Suchmaschine für Medizin und Gesundheit - indiziert auschliesslich deutschsprachige Lead Drug Receive Approval to Enter Clinical

HANDELSSIGNALE

Drug-Eluting Coronary Stents Utilizing Isotechnika's Lead Drug Receive Approval to Enter Clinical Trials Lead+Drug+Receive+Approval+to+Enter+Clinical

ots.at: das APA-OTS-Portal für multimediale Presseaussendungen

Drug-Eluting Coronary Stents Utilizing Isotechnika's Lead Drug Receive Approval to Enter Clinical ISA247 Positioned to Enter Phase II/III Clinical Trials

PRA International spricht während des europäischen Kongresses ...

Drug-Eluting Coronary Stents Utilizing Isotechnika's Lead Drug Receive Approval to Enter Clinical Trials FDA Approves Abbott's XIENCE(TM) V Drug Eluting Stent